ELUT
ELUTIA INC.
NASDAQ · Healthcare · Biotechnology · US
$0.81
−3.13%Oct 22, 2026, 20:05 UTC
Elutia announced that it will release its third-quarter 2026 financial results after market close on November 5, 2026.
Source:Oct 1, 2026, 20:45 UTC
Boston Scientific released the full $8 million escrow holdback to Elutia in connection with Elutia's sale of its BioEnvelope business to Boston Scientific.
Source:Aug 18, 2026, 12:00 UTC
Elutia Inc. completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for up to $11 million in cash, including $8 million at closing and up to $3 million in milestone payments.
Aug 13, 2026, 20:05 UTC
Elutia Inc. secured a $15 million loan financing agreement with Avenue Capital Group, with $10 million funded at closing and a second $5 million tranche to be unlocked upon FDA 510(k) clearance of NXT-41x, to fund the launch of its antibiotic-eluting biomatrix in the plastic and reconstructive surgery market.
Jul 16, 2026, 20:21 UTC
Cellution Biologics Inc. signs a definitive agreement to acquire the SimpliDerm® Human Hydrated Acellular Dermal Matrix business from Elutia Inc., expanding its allograft portfolio and entering the U.S. breast reconstruction market.
Source:Jul 16, 2026, 20:05 UTC
Elutia signed a definitive agreement to sell SimpliDerm in a transaction valued at up to $11 million.
Source:Jun 16, 2026, 00:00 UTC
Elutia Inc. elected David Colpman and Kevin Rakin as Class III directors, effective June 11, 2026.